Trial · NCT02024867
Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage
NCT02024867, Not applicable, Completed, Lucy Holmes, MD; results first posted 2014-09-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage. Trials, record NCT02024867. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02024867
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage
- NCT number
- NCT02024867
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 249 participants, actual
- Lead sponsor
- Lucy Holmes, MD
- Conditions
- Skin Disease, Bacterial, Abscess
- Interventions
- Trimethoprim-Sulfamethoxazole
- First posted
- 2013-12-31
- Last updated
- 2015-10-19
- Results first posted
- 2014-09-15
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment Failures | up to 2 weeks after surgical drainage | Treatment failures were defined as persistent or increased size of the original abscess requiring further medical or surgical intervention. Treatment cure was defined as no or minimal tenderness, erythema, fever, wound drainage, warmth, fluctuance or induration at the 10 to 14 day follow-up. |
| Primary | Treatment Failures Among Patients Infected With Methicillin-Resistant Staphylococcus Aureus | up to 2 weeks after surgical drainage | Treatment failures were defined as persistent or increased size of the original abscess requiring further medical or surgical intervention. Treatment cure was defined as no or minimal tenderness, erythema, fever, wound drainage, warmth, fluctuance or induration at the 10 to 14 day follow-up. |
| Primary | Treatment Failures Among Patients Infected With Methicillin-Sensitive Staphylococcus Aureus | up to 2 weeks after surgical drainage | Treatment failures were defined as persistent or increased size of the original abscess requiring further medical or surgical intervention. Treatment cure was defined as no or minimal tenderness, erythema, fever, wound drainage, warmth, fluctuance or induration at the 10 to 14 day follow-up. |
| Secondary | Recurrent Skin Infections | 1 month after surgical drainage | Rate of recurrent skin infection among follow-up responders 1 month after enrollment. Patients who were treatment failures were excluded from this analysis since they all received additional medical intervention that could affect the outcome measure. |
| Secondary | Recurrent Skin Infections Among Patients Infected With Methicillin-Resistant Staphylococcus Aureus | 1 month after surgical drainage | Rate of recurrent skin infection among follow-up responders 1 month after enrollment. Patients who were treatment failures were excluded from this analysis since they all received additional medical intervention that could affect the outcome measure. |
| Secondary | Recurrent Skin Infections Among Patients Infected With Methicillin-Sensitive Staphylococcus Aureus | 1 month after surgical drainage | Rate of recurrent skin infection among follow-up responders 1 month after enrollment. Patients who were treatment failures were excluded from this analysis since they all received additional medical intervention that could affect the outcome measure. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Treatment Failures | up to 2 weeks after surgical drainage | participants | NUMBER | |
| SECONDARY | Recurrent Skin Infections | 1 month after surgical drainage | participants | NUMBER | |
| PRIMARY | Treatment Failures Among Patients Infected With Methicillin-Resistant Staphylococcus Aureus | up to 2 weeks after surgical drainage | participants | NUMBER | |
| PRIMARY | Treatment Failures Among Patients Infected With Methicillin-Sensitive Staphylococcus Aureus | up to 2 weeks after surgical drainage | participants | NUMBER | |
| SECONDARY | Recurrent Skin Infections Among Patients Infected With Methicillin-Resistant Staphylococcus Aureus | 1 month after surgical drainage | participants | NUMBER | |
| SECONDARY | Recurrent Skin Infections Among Patients Infected With Methicillin-Sensitive Staphylococcus Aureus | 1 month after surgical drainage | participants | NUMBER |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Treatment Failures | 3 Days | 9 | participants | ||
| Treatment Failures | 10 Days | 4 | participants | ||
| Recurrent Skin Infections | 3 Days | 21 | participants | ||
| Recurrent Skin Infections | 10 Days | 9 | participants | ||
| Treatment Failures Among Patients Infected With Methicillin-Resistant Staphylococcus Aureus | 3 Days | 8 | participants | ||
| Treatment Failures Among Patients Infected With Methicillin-Resistant Staphylococcus Aureus | 10 Days | 1 | participants | ||
| Treatment Failures Among Patients Infected With Methicillin-Sensitive Staphylococcus Aureus | 3 Days | 1 | participants | ||
| Treatment Failures Among Patients Infected With Methicillin-Sensitive Staphylococcus Aureus | 10 Days | 1 | participants | ||
| Recurrent Skin Infections Among Patients Infected With Methicillin-Resistant Staphylococcus Aureus | 3 Days | 8 | participants | ||
| Recurrent Skin Infections Among Patients Infected With Methicillin-Resistant Staphylococcus Aureus | 10 Days | 2 | participants |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 3 Days | 134 | |
| Overall Study | STARTED | 10 Days | 131 | |
| Overall Study | COMPLETED | 3 Days | 125 | |
| Overall Study | COMPLETED | 10 Days | 124 | |
| Overall Study | NOT COMPLETED | 3 Days | 9 | |
| Overall Study | NOT COMPLETED | 10 Days | 7 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 3 Days | ||
| Total, all-cause mortality | 10 Days | ||
| Total, other adverse events | 3 Days | 0 | 125 |
| Total, other adverse events | 10 Days | 0 | 124 |
| Total, serious adverse events | 3 Days | 0 | 125 |
| Total, serious adverse events | 10 Days | 0 | 124 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons7
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| 3 Days vs 10 Days: Recurrent Skin Infections | Trial comparisons |
| 3 Days vs 10 Days: Recurrent Skin Infections Among Patients Infected With Methicillin-Sensitive Staphylococcus Aureus | Trial comparisons |
| 3 Days vs 10 Days: Treatment Failures Among Patients Infected With Methicillin-Sensitive Staphylococcus Aureus | Trial comparisons |
| 3 Days vs 10 Days: Treatment Failures Among Patients Infected With Methicillin-Resistant Staphylococcus Aureus | Trial comparisons |
| 3 Days vs 10 Days: Treatment Failures | Trial comparisons |
| 3 Days vs 10 Days: Recurrent Skin Infections Among Patients Infected With Methicillin-Resistant Staphylococcus Aureus | Trial comparisons |
| 3 Days vs 10 Days: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02024867
GET https://conductscience.org/api/trials/v1/NCT02024867/registered